Business Wire

FL-ELEVATE-PRIZE

4.11.2021 17:02:13 CET | Business Wire | Press release

Share
The Elevate Prize Foundation Announces its Second Annual Elevate Prize, Awarding Ten Social Entrepreneurs with $5 Million to Amplify Their Impact in Driving World Change

The Elevate Prize Foundation, in collaboration with MIT Solve, announced today the winners of the second annual Elevate Prize, which distributes $5 million across 10 diverse social entrepreneurs working to solve pressing issues around the world. This year’s winners, selected from a pool of over 1,200 applicants, stand out for their innovative approaches to global causes, such as LGBTQIA+ rights, access to health care, social justice reform and sustainability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005942/en/

Founded in 2019 by Joseph Deitch, The Elevate Prize Foundation aims to “Make Good Famous” by partnering with rising activists and social entrepreneurs and providing them with resources to raise visibility of their work, multiplying their ability to mobilize support – whether online or on-the-ground. The 2021 winners of the Elevate Prize will each receive a minimum of $300,000 in prize funding, as well as leadership development services, social media training, mentorship, and other support needed to reach a wider audience and grow their following.

“This year’s Elevate Prize winners are an exceptional group of creative problem-solvers who have managed to catalyze change through such challenging times,” said Joseph Deitch, Founder, Elevate Prize Foundation. “In a world that is increasingly looking for leaders to lead … and to inspire us, we are so fortunate to have these incredible individuals and organizations show us the way. We look forward to partnering and co-creating with them to expand their impact, and to share their stories with the world.”

The winners of the 2021 Elevate Prize are:

  • Amanda Alexander, Detroit Justice Center , which works alongside communities to transform the justice system and promote equitable and fair cities.
  • Krista Donaldson, Equalize Health , which provides access to medical care and addresses the leading causes of maternal and newborn mortality through innovative tech.
  • Aparna Hegde, ARMMAN , which uses mobile technology to enable healthy pregnancies, safe deliveries, and healthy childhoods.
  • Kaushik Kappangantulu, Kheyti , which designs, adapts and implements low-cost farming solutions to help farmers increase yield and predictability of produce, offering a “greenhouse-in-a-box” – an affordable, modular greenhouse bundled with full-stack services.
  • Nisha Ligon, Ubongo , the leading children’s entertainment producer in Africa, which harnesses the power of entertainment to reduce inequalities in education across Africa.
  • Heejae Lim, TalkingPoints , which connects and empowers families in under-resourced, multilingual communities, using communications technology to bridge crucial gaps between students, families, teachers, and schools.
  • Uzoma Orchingwa , Ameelio , which works to reduce the prison population, decrease recidivism and ensure incarcerated individuals can stay in touch with the outside through free-to-use communication apps.
  • Alexander Roque, Ali Forney Center , a space dedicated to empowering homeless LGBTQIA+ youth to live independently and get back on their feet.
  • Rebecca van Bergen, Nest , which supports the responsible growth and creative engagement of the artisan and maker economy to build a world of greater gender equity and economic inclusion.
  • Tony Weaver , Weird Enough Productions , which runs a national education program that combines diverse comic books with an anti-racist and equity-based learning curricula.

“We’re thrilled to highlight such a radically diverse group of winners this year, all working on a wide-range of important issues around the world,” said Carolina García Jayaram, CEO of The Elevate Prize Foundation. “We look forward to helping grow their audience and impact, ultimately making philanthropy and social change more accessible to all.”

The Elevate Prize 2021 winners were selected by a renowned judging panel, composed of purpose-driven leaders in business, academia, media and beyond, including Diane von Furstenberg, fashion designer and philanthropist; Maria Elena Salinas, journalist and CBS news contributor; Stephanie Mehta, Editor-in-Chief of Fast Company; and Natalie Tran, Executive Director of the CAA Foundation.

About The Elevate Prize Foundation

Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, The Elevate Prize Foundation aims to serve as an engine for social good by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize, which is awarded to 10 or more global leaders tackling pressing issues in innovative ways. The Elevate Prize Catalyst Award, another one of the Foundation’s programs, recognizes prominent individuals for their commitment to inspiring global social action and using their influence for the good of humanity. Through the Elevate Giving program, the Foundation allows everyday people the opportunity to engage in philanthropy. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook , Instagram , LinkedIn , and Twitter .

About MIT Solve

Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye